PMP22 and hereditary neuropathy with liability to pressure palsies: Given that treatments that excessively reduce PMP22 have the potential to cause HNPP-like symptoms, an accurate estimation of total PMP22 expression is crucial for predicting the therapeutic window of PMP22-targeting drugs between efficacy and adverse effects.